Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer.

ABSTRACT:

Purpose

To evaluate the tolerability of escalating doses of stereotactic body radiation therapy in the treatment of localized prostate cancer.

Patients and methods

Eligible patients included those with Gleason score 2 to 6 with prostate-specific antigen (PSA) ≤ 20, Gleason score 7 with PSA ≤ 15, ≤ T2b, prostate size ≤ 60 cm(3), and American Urological Association (AUA) score ≤ 15. Pretreatment preparation required an enema and placement of a rectal balloon. Dose-limiting toxicity (DLT) was defined as grade 3 or worse GI/genitourinary (GU) toxicity by Common Terminology Criteria of Adverse Events (version 3). Patients completed quality-of-life questionnaires at defined intervals.

Results

Groups of 15 patients received 45 Gy, 47.5 Gy, and 50 Gy in five fractions (45 tot

SUBMITTER: Boike TP 

PROVIDER: S-EPMC3138546 | biostudies-literature | 2011 May

REPOSITORIES: biostudies-literature